Oral contraceptive approved for acne vulgaris

February 5, 2007

Birth control pill Yaz, containing a combination of drospirenone 3 mg and ethinyl estradiol 20 mcg, has received approval for yet another indication—the treatment of acne vulgaris in women who desire an oral contraceptive for birth control. According to manufacturer Berlex, this marks the first time an oral contraceptive has received approval for three indications. Yaz was previously indicated as an oral contraceptive and as a treatment for the emotional and physical symptoms of premenstrual dysphoric disorder (PMDD). The drospirenone component has mineralocorticoid and antiandrogenic properties, the latter of which blocks male sex hormones that can cause acne.

Birth control pill Yaz, containing a combination of drospirenone 3 mg and ethinyl estradiol 20 mcg, has received approval for yet another indication—the treatment of acne vulgaris in women who desire an oral contraceptive for birth control. According to manufacturer Berlex, this marks the first time an oral contraceptive has received approval for three indications. Yaz was previously indicated as an oral contraceptive and as a treatment for the emotional and physical symptoms of premenstrual dysphoric disorder (PMDD). The drospirenone component has mineralocorticoid and antiandrogenic properties, the latter of which blocks male sex hormones that can cause acne.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.